Follow Us
© 2026 Arizent. All rights reserved.
The Food and Drug Administration approved two new weight-loss drugs last summer, but neither has achieved blockbuster status, and industry analysts don’t expect them to anytime soon.
Qsymia, manufactured by Vivus, has been available since last September. It’s a combination product with two active ingredients – one that works to decrease appetite and another that helps increase feelings of fullness.
Andrea Davis is the former editor-in-chief of Employee Benefit News, the leading publication for the employee benefits industry. An award-winning journalist and editor, Andrea has covered the … Read full bio
For reprint and licensing requests for this article, click here.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
Multiple experts weigh in on the challenges and considerations benefit leaders need to keep in mind as they make decisions about medication coverage.
Rising use of the weight-loss drug is fueling the fastest health plan cost growth in a decade and a half, forcing employers to rethink coverage strategies and cost management.
To truly flip the script on metabolic disease, benefit leaders must build a cost-efficient, supportive plan for employees and their business.
